Oncolytic viruses
A virus backbone edited to replicate only in tumour cells and a transgene it carries to call the immune system in. The grid below is virus backbone against transgene: 2 by 3 from 5 medicines, 2 combinations approved, 2 in development, 0 tried and stopped, 2 untried in this corpus.
Every tried combination
| Medicines | Records | Stopped, and why | ||||||
|---|---|---|---|---|---|---|---|---|
| Herpes simplex virus 1 | GM-CSF | Approved | 2 | 0 | 0 | Complete response letter citing trial design and heterogeneity | ||
| Herpes simplex virus 1 | Anti-PD-1 | In development | 0 | 1 | 0 | - | ||
| Adenovirus | GM-CSF | In development | 0 | 1 | 0 | - | ||
| Adenovirus | No transgene stated (deletion-based selectivity) | Approved | 1 | 0 | 0 | - |
Stopped, and why
0 medicines recorded as stopped; 1 recorded reason, including stopped studies of medicines still in development- Vusolimogene oderparepvecApproved
Complete response letter citing trial design and heterogeneity
Not placed
3 of 8 medicines in this format (37%)These medicines belong to the format but their virus backbone is on no record the engine reads: the targets field is empty, the target lists no such drug, the trials linked to it name no target of its own, and the modality, mechanism and summary text name none the corpus knows. They are listed here rather than placed by guesswork; adding the virus backbone to the record puts them in the grid on the next build.
How this grid is read from the records
Each medicine's parts come from its own record: the targets field first, else the target records that list the medicine, else a sibling conjugate that shares its antibody name, else the trials linked to it, else the target names the corpus knows found in its modality, mechanism or summary text. The second part is read from the medicine's technology links first and from its modality and mechanism text second; a part no record names is shown as not recorded. Every part carries the fields it was read from and a confidence in the JSON file.
What the states mean, and do not
Approved: a medicine in the cell has an approval row or a regulator's approved entry and is not recorded as withdrawn. In development: a recruiting, active or planned trial, a development-phase record status, or active studies in the ClinicalTrials.gov index, and no approval. Tried and stopped: every medicine in the cell is withdrawn, negative or historic, or its only trial evidence is a terminated, withdrawn or negative study, or its approval was withdrawn. Untried: no medicine in this corpus combines the two parts.
A cell is coloured by its strongest medicine; the table shows each medicine with its own state. The reasons quoted under Stopped, and why are the records' words, including the registry's whyStopped text where the sponsor wrote one, and include stopped studies of medicines that are still in development elsewhere. Nothing here is medical advice.